Aspirin may reduce cancer mortality
This article was originally published in The Tan Sheet
Executive Summary
Regular aspirin use may lower the risk of cancer-specific mortality among patients diagnosed with nonmetastatic colorectal cancer, according to a Journal of the American Medical Association study. Of the 840 women and 439 men participating in the Nurses' Health Study and the Health Professionals Follow-Up Study, 222 died from colorectal cancer. Only 15 percent of these deaths occurred among regular aspirin users, whereas 19 percent of deaths occurred among subjects who did not regularly use aspirin after their diagnosis, according to lead researcher Andrew Chan of Massachusetts General Hospital and Harvard Medical School and his associates. The results suggest this cancer type is sensitive to aspirin's potential anticancer effect, though cyclo-oxygenase-2-negative tumors might be aspirin-resistant
You may also be interested in...
Study Suggests Aspirin Use Enhances Survival After Breast Cancer
Aspirin use after the diagnosis of stage I to III breast cancer was associated with a decreased risk of breast cancer death and distant recurrence - when cancer has metastasized to another part of the body - according to results from the ongoing Nurses' Health Study
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.